Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase.

MLA

Xiong, Qi, et al. “Post-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Response to Anti-PD-1/PD-L1 Antibody in SCLC Patients at Early Phase.” Cancer Immunology, Immunotherapy : CII, vol. 70, no. 3, Mar. 2021, pp. 713–20. EBSCOhost, https://doi.org/10.1007/s00262-020-02706-5.

APA

Xiong, Q., Huang, Z., Xin, L., Qin, B., Zhao, X., Zhang, J., Shi, W., Yang, B., Zhang, G., & Hu, Y. (2021). Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase. Cancer Immunology, Immunotherapy : CII, 70(3), 713–720. https://doi.org/10.1007/s00262-020-02706-5

Chicago

Xiong, Qi, Ziwei Huang, Lingli Xin, Boyu Qin, Xiao Zhao, Jing Zhang, Weiwei Shi, Bo Yang, Guoqing Zhang, and Yi Hu. 2021. “Post-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Response to Anti-PD-1/PD-L1 Antibody in SCLC Patients at Early Phase.” Cancer Immunology, Immunotherapy : CII 70 (3): 713–20. doi:10.1007/s00262-020-02706-5.